IVAC_M_uID

P1, N=42, Completed, BioNTech SE | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> May 2023

In a third arm, patients were vaccinated with IVAC_M_uID, an on-demand manufactured Individualized NeoAntigen Specific Immunotherapy (iNeST) encoding neoepitopes derived from up to 20 cancer mutations determined by next generation sequencing (NGS)...Vaccine-induced CD8+ T cells were of effector/memory, PD1+ phenotype, with a high fraction IFNγ/TNFα/Mip-1a&b triple-positive. This first data suggests that the vaccine is highly efficient in inducing strong poly-epitopic T-cell responses in patients with TNBC in the post-(neo) adjuvant setting, justifying further trials to assess the efficacy of the vaccine in this patient population.

P1, N=42, Active, not recruiting, BioNTech SE | Trial completion date: Nov 2020 --> Dec 2023

In a third arm, patients were vaccinated with IVAC_M_uID, an on-demand manufactured Individualized NeoAntigen Specific Immunotherapy (iNeST) encoding neoepitopes derived from up to 20 cancer mutations determined by NGS...Funding: BioNTech SE. Clinical trial identification: NCT02316457.

P1, N=39, Active, not recruiting, Biontech SE | Trial completion date: Apr 2020 --> Nov 2020 | Trial primary completion date: Dec 2019 --> Jun 2020